🟢 ABCL surges 5.4% today, fueled by recent Jazz Pharmaceuticals collaboration

ABCL is trading 5.4% up today at $6.36, extending a strong multi-day run that has lifted the stock more than 20% over the past week.

• This rally follows the company's recent collaboration with Jazz Pharmaceuticals, announced on June 17, 2026, to discover and develop next-generation T-cell-engaging multispecific antibodies for various cancers.
• This strategic partnership, which includes an upfront payment of $56 million and potential milestone payments up to $792 million per program, has drawn fresh investor attention and is cited by analysts as a key driver of the stock's upside trend.
• The stock also saw a 7.1% gain on June 24, with increased trading volume, indicating strong market interest in the company's developments.